Inhibition of Glycogen Synthase Kinase-3 Increases the Cytotoxicity of Enzastaurin
Authors:
- 1 July 2011
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 131 (7) , 1442-1449
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaLeukemia & Lymphoma, 2011
- CD44 Attenuates Activation of the Hippo Signaling Pathway and Is a Prime Therapeutic Target for GlioblastomaCancer Research, 2010
- Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signalingBlood, 2009
- Differential Activation of ERK and Rac Mediates the Proliferative and Anti-proliferative Effects of Hyaluronan and CD44Journal of Biological Chemistry, 2008
- The β-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expressionRNA, 2008
- Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 ExpressionCell, 2008
- Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cellsBlood, 2007
- The Selective Protein Kinase C β Inhibitor Enzastaurin Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines through the AKT PathwayJournal of Investigative Dermatology, 2006
- CD44 cross-linking induces protein kinase C-regulated migration of human T lymphocytesInternational Immunology, 2005
- Crossregulation of NF‐κB by the APC/GSK‐3β/β‐catenin pathwayMolecular Carcinogenesis, 2004